Sjögren's syndrome. Current aspects from a rheumatological point of view;Sjögren-syndrom. Aktuelle aspekte aus rheumatologischer sicht

Zeitschrift fur Rheumatologie

Volumn 65, Issue 6, 2006, Pages 505-519

  Tomiak, C ^a   Dorner T ^b  

^a Neurologische Klinik Bad Aibling   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Extraglandular manifestations; Non Hodgkin's lymphoma; Sicca symptomatology; Sj gren's syndrome; Therapy

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BROMHEXINE; CEVIMELINE; CHLOROQUINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXPANTHENOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; ESTROGEN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MUCOLYTIC AGENT; PILOCARPINE; PREDNISOLONE; PROTON PUMP INHIBITOR; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; EXOCRINE GLAND; HUMAN; INNER EAR DISEASE; KERATOCONJUNCTIVITIS; LYMPHOCYTIC INFILTRATION; MEDICAL SPECIALIST; MUSCULOSKELETAL DISEASE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PREVALENCE; REVIEW; SJOEGREN SYNDROME; STOMATITIS; STOMATITIS SICCA; SYMPTOMATOLOGY;

ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; COOPERATIVE BEHAVIOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; KERATOCONJUNCTIVITIS SICCA; LYMPHOMA, B-CELL; PATIENT CARE TEAM; RIBONUCLEOPROTEINS; RISK FACTORS; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 33750305244     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-006-0101-0     Document Type: Review

References (21)

1. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ (1965) Sjögren's syndrome, a clinical, pathological and serological study of sixty-two cases. Medicine 44: 187-231
2. Callaghan R, Prabu A, Allan RB et al. (2006) Direct healthcare costs and predictors of costs in patients with primary Sjögren's syndrome. Rheumatology 25 (Epub ahead of print)
3. Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol 21: 656-660
4. Dörner T (2001) Neonatale Lupus-syndrome. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie. Springer, Berlin Heidelberg New York Tokyo, S 865-894
5. Dörner T, Gromnica-Ihle E (2006) Sjögren-Syndrom, Kapitel 4.1. In: Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier/Urban Fischer, München Jena
6. Drosos AA, Skopouli FN, Costopoulos JS et al. (1986) Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis 45(9): 732-735
7. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjögren's syndrome with hydroxychloroquin: a retrospective, openlabel study. Lupus 5 [Suppl 1]: S31-S36
8. Groom J, Kalled SL, Cutler AH et al. (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109(1): 59-68
9. Hansen A, Gosemann M, Pruss A et al. (2004) Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum 50: 1897-1908
10. Hansen A, Lipsky PE, Dorner T (2005) Immunopathogenesis of primary Sjogren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17(5): 558-565
11. Hansen A, Reiter K, Pruss A et al. (2006) Dissemination of a Sjögren's syndrome-associated extranodal marginal zone B cell lymphoma. Arthritis Rheum 54: 127-137
12. Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77: 24-28
13. Kassan SS, Thomas TL, Moutsopoulos HM et al. (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6): 888-892
14. Manthorpe R (2005) Wie klassifizieren wir Patienten, bei den wir ein Sjögren-Syndrom vermuten? Geschichtliche Entwicklung verschiedener Klassifikationen und vermutliche Weiterentwicklung. Akt Rheumatol 30: 32-37
15. Niederkorn JY, Stern ME, Pflugfelder SC et al. (2006) Desiccating stress induces T cell-mediated Sjogren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol 176(7): 3950-3957
16. Paulsen FP, Schaudig U, Thale AB (2003) Drainage of tears: impact on the ocular surface and lacrimal system. Clin Sci 1(4): 180-191
17. Pijpe J, van Imhoff GW, Spijkervet FK et al. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52(9): 2740-2750
18. Ramos-Casals M, Nardi N, Brito-Zeron P et al. (2006) Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35(5): 312-321
19. Sjögren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmologica, Copenhagen [Suppl II]: 1-151
20. Stiller M (2005) Die orale Komponente des Sjögren-Syndroms - diagnostische Aspekte und zahnmedizinisch-therapeutische Konsequenzen. Akt Rheumatol 30: 41-45
21. Vitali C, Bombardieri S, Jonsson R et al. (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the America-European-Consensus Group. Ann Rheum Dis 61: 554-558